StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Diluted EPS Impact of Prior-Period Revenue True-Ups by Quarter

Diluted EPS Impact of Prior-Period Revenue True-Ups ($/sh) ($)

QuarterlyAnnual

Natera Diluted EPS Impact of Prior-Period Revenue True-Ups: $0.36 in Q2 2026, up 9.1% from a year earlier.

Latest, Q2 2026
0.36
Period ended Jun 30, 2026
Change on a year earlier
+9.1%
0.33 in Q2 2025
History
11 quarters
Since Q1 2023
Sources
8
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (2026-08-07) ↗

Reported in Form 10-K/10-Q Note — Cumulative Catch-Up Revenue Adjustment (XBRL).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiluted EPS Impact of Prior-Period Revenue True-Ups ($/sh) ($)Year on yearSource
Q2 2026Jun 30, 20260.36+9.1%Form 10-Q (2026-08-07) ↗
Q1 2026Mar 31, 20260.43+72.0%Form 10-Q (2026-05-08) ↗
Q3 2025Sep 30, 20250.40+42.9%Form 10-Q (2025-11-07) ↗
Q2 2025Jun 30, 20250.33+3.1%Form 10-Q (2026-08-07) ↗
Q1 2025Mar 31, 20250.25-10.7%Form 10-Q (2026-05-08) ↗
Q3 2024Sep 30, 20240.28+1,300.0%Form 10-Q (2025-11-07) ↗
Q2 2024Jun 30, 20240.32+966.7%Form 10-Q (2025-08-08) ↗
Q1 2024Mar 31, 20240.28-450.0%Form 10-Q (2025-05-09) ↗
Q3 2023Sep 30, 20230.02–Form 10-Q (2024-11-12) ↗
Q2 2023Jun 30, 20230.03–Form 10-Q (2024-08-09) ↗
Q1 2023Mar 31, 2023-0.08–Form 10-Q (2024-05-10) ↗

Cite this data

StockData. (2026). Natera Diluted EPS Impact of Prior-Period Revenue True-Ups ($), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/eps-prior-period-trueup

See every metric in the Natera KPI table. Data updated Nov 2, 2026.